In the REGARD exploratory biomarkers analysis, the authors evaluated patients’ serum and tumor samples, aiming at correlating ramucirumab efficacy with biomarker expression, including VEGFR family, HER2, VEGF-C and -D. This evidence concerns the gene ERBB2 and neoplasm.